Hear hear! Ear gene ther­a­py play­er Ak­ou­os draws $105M in fresh cap­i­tal

Come on, come on, lis­ten to the mon­ey talk.

Thriv­ing on the mo­men­tum of biotech­nol­o­gy com­pa­nies work­ing on ther­a­pies to ad­dress hear­ing loss, Boston-based Ak­ou­os has scored $105 mil­lion in an over­sub­scribed Se­ries B fi­nanc­ing, less than two years af­ter an NEA, 5AM Ven­tures-backed $50 mil­lion haul.

Ak­ou­os — Greek for ‘to hear’ — is de­vel­op­ing gene ther­a­pies en­gi­neered to re­store, im­prove or pre­serve hear­ing. Along with its part­ners — the world’s largest hear­ing re­search cen­ter Mass­a­chu­setts Eye and Ear, as well as Swiss Alps-based vi­ral gene and cell ther­a­py mak­er Lon­za — Ak­ou­os is at the cusp of tak­ing its lead ther­a­py in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.